Ocular Therapeutix, Inc (OCUL) stock
OCULNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 9, 2026Score 3/3011% above fair value
$6.02+0.01 (+0.17%)
Close on Nov 17, 2026Market cap $1.32BP/E –Yield –
Ocular Therapeutix operating margin
Operating margin is operating income as a percentage of revenue.
Ocular Therapeutix's operating margin for the twelve months ending Jun 30, 2026 was -603.0%. For fiscal 2025 it was -519.8%, against -269.6% the year before. The highest annual figure on record is -141.0% in fiscal 2023.
Annual operating margin
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -519.8% | −250.2 |
| FY2024 | Dec 31, 2024 | -269.6% | −128.6 |
| FY2023 | Dec 31, 2023 | -141.0% | +11.8 |
| FY2022 | Dec 31, 2022 | -152.7% | +26.6 |
| FY2021 | Dec 31, 2021 | -179.3% | +181.8 |
| FY2020 | Dec 31, 2020 | -361.1% | +1668.7 |
| FY2019 | Dec 31, 2019 | -2029.9% | +940.9 |
| FY2018 | Dec 31, 2018 | -2970.8% | +249.4 |
| FY2017 | Dec 31, 2017 | -3220.1% | −924.1 |
| FY2016 | Dec 31, 2016 | -2296.0% | −113.3 |
| FY2015 | Dec 31, 2015 | -2182.7% | +1326.9 |
| FY2014 | Dec 31, 2014 | -3509.6% | +133200.4 |
| FY2012 | Dec 31, 2012 | -136710.0% | – |
Quarterly operating margin
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change (pts) |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -609.3% | −106.8 |
| Q1 FY2026 | Mar 31, 2026 | -865.5% | −268.0 |
| Q4 FY2025 | Dec 31, 2025 | -526.5% | −230.4 |
| Q3 FY2025 | Sep 30, 2025 | -472.3% | −174.1 |
| Q2 FY2025 | Jun 30, 2025 | -502.6% | −237.4 |
| Q1 FY2025 | Mar 31, 2025 | -597.5% | −383.5 |
| Q4 FY2024 | Dec 31, 2024 | -296.1% | −160.6 |
| Q3 FY2024 | Sep 30, 2024 | -298.2% | −170.8 |
| Q2 FY2024 | Jun 30, 2024 | -265.1% | −129.7 |
| Q1 FY2024 | Mar 31, 2024 | -214.0% | −45.4 |
| Q4 FY2023 | Dec 31, 2023 | -135.5% | +2.1 |
| Q3 FY2023 | Sep 30, 2023 | -127.4% | +52.7 |
| Q2 FY2023 | Jun 30, 2023 | -135.5% | +26.9 |
| Q1 FY2023 | Mar 31, 2023 | -168.6% | −33.4 |
| Q4 FY2022 | Dec 31, 2022 | -137.6% | +9.1 |
| Q3 FY2022 | Sep 30, 2022 | -180.1% | −19.4 |
| Q2 FY2022 | Jun 30, 2022 | -162.4% | +10.3 |
| Q1 FY2022 | Mar 31, 2022 | -135.2% | +140.3 |
| Q4 FY2021 | Dec 31, 2021 | -146.6% | +48.5 |
| Q3 FY2021 | Sep 30, 2021 | -160.7% | +77.7 |
| Q2 FY2021 | Jun 30, 2021 | -172.6% | +967.2 |
| Q1 FY2021 | Mar 31, 2021 | -275.5% | +361.3 |
| Q4 FY2020 | Dec 31, 2020 | -195.2% | +753.5 |
| Q3 FY2020 | Sep 30, 2020 | -238.4% | +2553.4 |
| Q2 FY2020 | Jun 30, 2020 | -1139.8% | +2183.1 |
| Q1 FY2020 | Mar 31, 2020 | -636.8% | +3358.7 |
| Q4 FY2019 | Dec 31, 2019 | -948.6% | +2480.5 |
| Q3 FY2019 | Sep 30, 2019 | -2791.8% | +183.3 |
| Q2 FY2019 | Jun 30, 2019 | -3322.9% | −1229.7 |
| Q1 FY2019 | Mar 31, 2019 | -3995.5% | −38.2 |
| Q4 FY2018 | Dec 31, 2018 | -3429.2% | −818.1 |
| Q3 FY2018 | Sep 30, 2018 | -2975.1% | −69.6 |
| Q2 FY2018 | Jun 30, 2018 | -2093.2% | +2093.8 |
| Q1 FY2018 | Mar 31, 2018 | -3957.4% | −658.0 |
| Q4 FY2017 | Dec 31, 2017 | -2611.1% | −170.4 |
| Q3 FY2017 | Sep 30, 2017 | -2905.5% | −968.9 |
| Q2 FY2017 | Jun 30, 2017 | -4187.0% | – |
| Q1 FY2017 | Mar 31, 2017 | -3299.4% | – |
| Q4 FY2016 | Dec 31, 2016 | -2440.7% | – |
| Q3 FY2016 | Sep 30, 2016 | -1936.7% | – |
See a number that looks wrong?